About Caroline

Caroline Vu's practice is directed on the representation of public and private biotechnology and pharmaceutical companies, in a variety of transactions, particularly those relating to strategic relationships for the research, development and commercialization of novel products and technologies.

View full bio

Experience

Kite Pharma Announces Clinical Collaboration with Humanigen

Kite Pharma Announces Clinical Collaboration with Humanigen

August 21, 2020

Cooley advised Kite Pharma, a Gilead company, dedicated to developing active immunotherapies, in the formation of a clinical collaboration with Humanigen, Inc. to conduct a Phase ½ study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The goal of this collaboration is to determine the effect of lenzilumab on the clinical profile of Yescarta. Financial terms were not disclosed. Cooley special counsel Caroline Vu advised Kite.

Related contacts

Caroline Vu
Special Counsel, Palo Alto

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences

Kite Pharma Announces Clinical Collaboration with Kiniksa Pharmaceuticals

Kite Pharma Announces Clinical Collaboration with Kiniksa Pharmaceuticals

August 21, 2020

Cooley advised Kite Pharma, a Gilead company, dedicated to developing active immunotherapies, in its clinical collaboration with Kiniksa Pharmaceuticals to conduct a Phase 2, multicenter study of mavrilimumab, an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma. The goal of this collaboration is to determine the effect of mavrilimumab on the clinical profile of Yescarta. Financial terms were not disclosed. Cooley special counsel Caroline Vu advised Kite.

Related contacts

Caroline Vu
Special Counsel, Palo Alto

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences

Xyphos Biosciences in its Research Collaboration and License Agreement with Parker Institute for Cancer Immunotherapy

Xyphos Biosciences in its Research Collaboration and License Agreement with Parker Institute for Cancer Immunotherapy

September 3, 2019

Cooley Advises DFJ on Growth Investment in Paradigm Health

Cooley Advises DFJ on Growth Investment in Paradigm Health

April 23, 2025

Cooley advised DFJ Growth on its growth investment in Paradigm Health, a company on a mission to bring equitable access to clinical trials. This investment will bolster Paradigm’s innovative efforts and accelerate its growth trajectory. DFJ Growth is a venture capital firm that focuses on investing in innovative, high-growth companies. Lawyer Sale Kwon led the Cooley team advising DFJ Growth.

Related contacts

Sale Kwon
Partner, Palo Alto
Alanna Anderson
Associate, Palo Alto
Caroline Vu
Special Counsel, Palo Alto

Related Practices & Industries

Emerging Companies
Venture Capital
Technology
Artificial Intelligence

Hengrui Pharmaceuticals Announces License Agreement With Merck KGaA

Hengrui Pharmaceuticals Announces License Agreement With Merck KGaA

April 8, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Caroline Vu
Special Counsel, Palo Alto
Letian Wei
Legal Consultant, Shanghai
Marc Suskin
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Rebecca Ross
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Jiqiang Lin
Associate, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Patent Counseling and Prosecution
Tax
Business Restructuring
Commercial Litigation
Antitrust and Competition
Cyber/Data/Privacy
CFIUS
Asia

Admissions and credentials

California

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.